Yaxiong Zhang

7PUBLICATIONS
16CO-AUTHORS
ChemotherapyMolecular targetsSolid tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Dec 02, 2024
Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT.

Huaqiang Zhou, Yuanyuan Zhao, Mingjun Zhang

|Sep 26, 2024
Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial.

Yaxiong Zhang, Yan Huang, Yunpeng Yang

|Aug 12, 2024
Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial.

Hua-Qiang Zhou, Ya-Xiong Zhang, Gang Chen

|Sep 15, 2021
Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer.

Huaqiang Zhou, Yi Hu, Rongzhen Luo

|Aug 11, 2021
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.

Shaodong Hong, Yaxiong Zhang, Gengsheng Yu

|Apr 05, 2019
The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer.

Yaxiong Zhang, Lianpeng Chang, Yunpeng Yang

Pageof 2

Frequent Collaborators

2 joint publications

Huaqiang Zhou

2 joint publications

Wenfeng Fang

2 joint publications

Li Zhang

1 joint publications

Shaodong Hong